1. Home
  2. MESO vs UDMY Comparison

MESO vs UDMY Comparison

Compare MESO & UDMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • UDMY
  • Stock Information
  • Founded
  • MESO 2004
  • UDMY 2009
  • Country
  • MESO Australia
  • UDMY United States
  • Employees
  • MESO N/A
  • UDMY N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • UDMY Other Consumer Services
  • Sector
  • MESO Health Care
  • UDMY Real Estate
  • Exchange
  • MESO Nasdaq
  • UDMY Nasdaq
  • Market Cap
  • MESO 1.3B
  • UDMY 1.1B
  • IPO Year
  • MESO N/A
  • UDMY 2021
  • Fundamental
  • Price
  • MESO $18.41
  • UDMY $6.76
  • Analyst Decision
  • MESO Buy
  • UDMY Buy
  • Analyst Count
  • MESO 2
  • UDMY 10
  • Target Price
  • MESO $24.00
  • UDMY $9.89
  • AVG Volume (30 Days)
  • MESO 283.4K
  • UDMY 1.7M
  • Earning Date
  • MESO 08-28-2025
  • UDMY 10-28-2025
  • Dividend Yield
  • MESO N/A
  • UDMY N/A
  • EPS Growth
  • MESO N/A
  • UDMY N/A
  • EPS
  • MESO N/A
  • UDMY N/A
  • Revenue
  • MESO $17,198,000.00
  • UDMY $795,538,000.00
  • Revenue This Year
  • MESO $288.50
  • UDMY $2.58
  • Revenue Next Year
  • MESO $173.73
  • UDMY $4.19
  • P/E Ratio
  • MESO N/A
  • UDMY N/A
  • Revenue Growth
  • MESO 191.39
  • UDMY 3.93
  • 52 Week Low
  • MESO $7.09
  • UDMY $5.68
  • 52 Week High
  • MESO $22.00
  • UDMY $10.61
  • Technical
  • Relative Strength Index (RSI)
  • MESO 70.00
  • UDMY 42.88
  • Support Level
  • MESO $15.60
  • UDMY $6.88
  • Resistance Level
  • MESO $16.19
  • UDMY $7.21
  • Average True Range (ATR)
  • MESO 0.54
  • UDMY 0.22
  • MACD
  • MESO 0.17
  • UDMY -0.04
  • Stochastic Oscillator
  • MESO 86.95
  • UDMY 3.85

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About UDMY Udemy Inc.

Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.

Share on Social Networks: